Microbiotica reported positive Phase Ib results for MB‑310, an oral live biotherapeutic for ulcerative colitis. In the randomized study, 12 of 19 treated patients achieved clinical remission versus three of 10 in placebo; responders sustained remission during three‑month follow‑up and showed histologic and mucosal biomarker improvements. The data support further development of MB‑310 and bolster momentum for oral live‑biotherapeutic approaches in inflammatory bowel disease. Microbiotica will use the Phase Ib findings to inform dose selection and registrational strategy, with next clinical milestones expected as the company advances toward larger efficacy trials.